Disease Areas

BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data

Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer

Labcorp, VieCure Collaborate on NGS, Software for Cancer Diagnosis

Tango Therapeutics Gets FDA Permission to Start Studying PRMT5 Inhibitor in MTAP-Deleted Cancers

Indivumed Sells Biospecimens Service Unit to CRO Crown Bioscience

Verastem Oncology Plans for FDA Submission of Avutometinib-Defactinib Combo in Ovarian Cancer

Geneseeq Nabs CE Marks for Residual Disease and Cancer Early Detection Tests

Ibex Inks Deal With AstraZeneca, Daiichi Sankyo to Develop AI-Based HER2 Scoring

ImmPact Bio to Begin Phase I/II Trial of Bispecific CAR T-Cell Therapy in Aggressive Lymphoma

Geneoscopy Submits PMA Application to FDA for Stool-Based Colorectal Cancer Screening Test

Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test

Viewpoint Molecular Targeting Treats First Neuroendocrine Cancer Patients With Radiopharmaceutical

Genetic Testing Challenges in Oncology: Patient With Pending Bill Has BRCA1 Result Withheld

Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment

Mirati Therapeutics' KRAS G12D Inhibitor Cleared by FDA to Begin Phase I/II Trial

FDA Approves Seagen's Tukysa, Genentech's Herceptin for HER2-Positive Colorectal Cancer Patients

In Brief This Week: Strata Oncology, Orphagen Pharmaceuticals, Hutchmed, MD Anderson Cancer Center